<DOC>
	<DOCNO>NCT00496704</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , capecitabine , oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose gemcitabine give together capecitabine oxaliplatin second-line therapy see well work treat patient advanced colorectal cancer previously treat irinotecan .</brief_summary>
	<brief_title>Gemcitabine , Capecitabine , Oxaliplatin Second-Line Therapy Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan</brief_title>
	<detailed_description>OBJECTIVES : Primary - Define dose-limiting toxicity maximum tolerate dose gemcitabine hydrochloride administer capecitabine oxaliplatin second-line therapy patient advance colorectal cancer previously treat irinotecan hydrochloride . ( Phase I ) - Determine recommend phase II dose gemcitabine hydrochloride patient . ( Phase I ) - Assess overall response rate patient treat regimen . ( Phase II ) Secondary - Assess progression-free survival patient treat regimen . ( Phase II ) - Assess time treatment failure , duration response , time response patient treat regimen . ( Phase II ) - Assess overall survival patient treat regimen . ( Phase II ) - Assess safety regimen patient . ( Phase II ) OUTLINE : This multicenter , phase I , dose-escalation study gemcitabine hydrochloride , follow phase II , open-label study . - Phase I : Patients receive gemcitabine hydrochloride IV 30 minute day 1 8 , oral capecitabine twice daily day 1-14 , oxaliplatin IV 2 hour day 1 . Courses repeat every 21 day . Cohorts 3-6 patient receive escalate dos gemcitabine hydrochloride maximum tolerate dose ( MTD ) determine . - Phase II : Patients receive gemcitabine hydrochloride MTD determine phase I capecitabine oxaliplatin phase I .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced colorectal adenocarcinoma Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan Must receive prior irinotecan hydrochloride progressionfree interval &lt; 3 month No symptomatic brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN ( 5 time ULN liver metastasis present ) Creatinine ≤ 1.5 time ULN No significant cardiac abnormality ECG No known hypersensitivity study drug components No myocardial infarction within past 12 month No uncontrolled congestive heart failure No cardiovascular disorder ≥ grade 3 despite treatment No malignancy invasive carcinoma diagnose within past 5 year , except adequately treat basal cell carcinoma skin situ carcinoma cervix No significant disease , opinion investigator , would preclude study treatment ( e.g. , active infection , interstitial lung disease , peripheral neuropathy ) No history significant neurological psychiatric disorder ( e.g. , dementia , seizure , bipolar disorder ) No legal incapacity limited legal capacity would preclude study participation PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy More 30 day since prior participation another clinical trial No concurrent warfarin , phenprocoumon , phenytoin , sorivudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>